Loading...
•
Mar 31, 2023
Cencora Q2 2023 Earnings Report
AmerisourceBergen reported strong financial results for Q2 2023, with revenue increasing by 9.9% year-over-year and adjusted diluted EPS rising by 8.7%.
Key Takeaways
AmerisourceBergen Corporation's Q2 2023 earnings showcased a robust 9.9% increase in revenue, reaching $63.5 billion. Adjusted diluted EPS grew by 8.7% to $3.50, reflecting the company's strong financial performance and strategic execution. The company raised its full-year financial outlook, demonstrating the value of its pharmaceutical-centric strategy and key strategic partnerships.
Revenue increased by 9.9% year-over-year to $63.5 billion.
GAAP diluted EPS was $2.13, while adjusted diluted EPS increased by 8.7% to $3.50.
U.S. Healthcare Solutions revenue increased by 11.3% year-over-year.
The company raised its adjusted diluted EPS guidance range for fiscal year 2023 to $11.70 to $11.90.
Cencora
Cencora
Forward Guidance
AmerisourceBergen is updating its fiscal year 2023 financial guidance to primarily reflect stronger core growth in the U.S. Healthcare Solutions segment. The Company now expects revenue growth to be in the range of 6 to 8 percent and Adjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90.
Positive Outlook
- Revenue growth to be in the range of 6 to 8 percent, up from the previous range of 5 to 7 percent.
- U.S. Healthcare Solutions revenue growth to be in the range of 7 to 8 percent, narrowed from the previous range of 6 to 8 percent.
- International Healthcare Solutions revenue to be in the range of a 3 percent decline to flat, up from the previous range of a 1 to 5 percent decline.
- Adjusted Diluted Earnings Per Share to be in the range of $11.70 to $11.90, representing growth of 6 to 8 percent, raised from the previous range of $11.50 to $11.75.
- Adjusted consolidated operating income growth to be in the range of 2 to 4 percent, up from the previous range of 0 to 3 percent.